Invention Grant
- Patent Title: Immunogenic conjugates and methods of use thereof
-
Application No.: US16760418Application Date: 2018-11-02
-
Publication No.: US11235046B2Publication Date: 2022-02-01
- Inventor: Paul J. Brett , Mary N. Burtnick
- Applicant: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA
- Applicant Address: US NV Reno
- Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA
- Current Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA
- Current Assignee Address: US NV Reno
- Agency: Schwabe, Williamson & Wyatt PC
- International Application: PCT/US2018/059043 WO 20181102
- International Announcement: WO2019/090138 WO 20190509
- Main IPC: A61K39/02
- IPC: A61K39/02 ; A61K47/64 ; A61P31/04 ; A61K39/00

Abstract:
Disclosed are capsular polysaccharide (CPS)-protein immunogenic conjugates useful for providing protection against any condition or disease associated with Burkholderia pseudomallei or Burkholderia mallei, such as melioidosis or glanders, respectively. For example, a disclosed CPS-protein immunogenic conjugate includes purified 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei chemically activated and covalently linked to recombinant CRM 197 diphtheria toxin mutant (CRM197) to produce CPS-CRM197. Methods of inducing an immune response are disclosed. The methods include the use of a CPS-protein immunogenic conjugate, alone or in conjunction with other agents, such as Hcp1 and TssM, to prevent infection with B. pseudomallei or B. mallei. Also disclosed are methods for treating a subject having melioidosis or glanders.
Public/Granted literature
- US20200338179A1 IMMUNOGENIC CONJUGATES AND METHODS OF USE THEREOF Public/Granted day:2020-10-29
Information query